# US 2006/0153836 A1 · Molecules and methods for inhibiting shedding of KIM-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153836 A1
- Document ID: US20060153836A1
- Status: Published application
- Kind: A1
- Application number: 11/349,852
- Filed: 2006-02-07
- Published: 2006-07-13
- Earliest claimed: 2001-06-01
- Assignees: Biogen Idec MA Inc., a Massachusetts corporation; The General Hospital Corporation, a Massachusetts corporation
- Inventors: Veronique Bailly; Joseph Bonventre
- Web page: https://patentgrep.com/patent/US20060153836A1

## CPC

- G01N 33/5011: {for testing antineoplastic activity}
- A61P 13/12: of the kidneys
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- G01N 33/5008: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 33/5044: {involving specific cell types}
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method of inhibiting release of a soluble form of a KIM-1 polypeptide from a cell, the method comprising contacting a cell expressing a KIM-1 cell surface polypeptide with an effective amount of an isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

### Claim 13 (depends on 12)

The method of claim 12, wherein the cell is a renal cell.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cell is in vitro.

### Claim 15 (depends on 12)

The method of claim 12, wherein the cell is in vivo.

### Claim 16

A method of inhibiting proteolysis of a KIM-1 polypeptide, the method comprising contacting a cell expressing a KIM-1 polypeptide with an effective amount of an isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

### Claim 17

A method of treating renal disease or injury in a mammal, the method comprising administering to the mammal an effective amount of an isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

### Claim 18 (depends on 17)

The method of claim 17, wherein the renal disease or injury is renal cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the renal cancer is renal carcinoma.

### Claim at position 10

20-21. (canceled)

### Claim 22 (depends on 17)

The method of claim 17, wherein the mammal is a human.

### Claim 23 (depends on 12)

The method of claim 12, wherein the antibody has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 24 (depends on 12)

The method of claim 12, wherein the antibody crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 25 (depends on 12)

The method of claim 12, wherein the antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 26 (depends on 12)

The method of claim 12, wherein the antibody binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

### Claim 27 (depends on 12)

The method of claim 12, wherein the antibody is a humanized antibody.

### Claim 28 (depends on 12)

The method of claim 12, wherein the antibody is a fully human antibody.

### Claim 29 (depends on 12)

The method of claim 12, wherein the antibody is a monoclonal antibody.

### Claim 30 (depends on 12)

The method of claim 12, wherein the antibody is a single chain antibody.

### Claim 31 (depends on 12)

The method of claim 12, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an Fab fragment, an F(ab′)2 fragment, an Fab′ fragment, an Fsc fragment, or an Fv fragment.

### Claim 32 (depends on 16)

The method of claim 16, wherein the antibody has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 33 (depends on 16)

The method of claim 16, wherein the antibody crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 34 (depends on 16)

The method of claim 16, wherein the antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 35 (depends on 16)

The method of claim 16, wherein the antibody binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

### Claim 36 (depends on 16)

The method of claim 16, wherein the antibody is a humanized antibody.

### Claim 37 (depends on 16)

The method of claim 16, wherein the antibody is a fully human antibody.

### Claim 38 (depends on 16)

The method of claim 16, wherein the antibody is a monoclonal antibody.

### Claim 39 (depends on 16)

The method of claim 16, wherein the antibody is a single chain antibody.

### Claim 40 (depends on 16)

The method of claim 16, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an Fab fragment, an F(ab′)2 fragment, an Fab′ fragment, an Fsc fragment, or an Fv fragment.

### Claim 41 (depends on 17)

The method of claim 17, wherein the antibody has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 42 (depends on 17)

The method of claim 17, wherein the antibody crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 43 (depends on 17)

The method of claim 17, wherein the antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

### Claim 44 (depends on 17)

The method of claim 17, wherein the antibody binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

### Claim 45 (depends on 17)

The method of claim 17, wherein the antibody is a humanized antibody.

### Claim 46 (depends on 17)

The method of claim 17, wherein the antibody is a fully human antibody.

### Claim 47 (depends on 17)

The method of claim 17, wherein the antibody is a monoclonal antibody.

### Claim 48 (depends on 17)

The method of claim 17, wherein the antibody is a single chain antibody.

### Claim 49 (depends on 17)

The method of claim 17, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an Fab fragment, an F(ab′)2 fragment, an Fab′ fragment, an Fsc fragment, or an Fv fragment.
